Denali Therapeutics Inc. (NASDAQ: DNLI) stock closed at 19.79 per share at the end of the most recent trading day (a -4.07% change compared to the prior day closing price) with a volume of 1.56M shares and market capitalization of 2.85B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 291 people. Denali Therapeutics Inc. CEO is Ryan J. Watts.

The one-year performance of Denali Therapeutics Inc. stock is -36.24%, while year-to-date (YTD) performance is -28.84%. DNLI stock has a five-year performance of -6.65%. Its 52-week range is between 19.67 and 34.78, which gives DNLI stock a 52-week price range ratio of 7.15%

Denali Therapeutics Inc. currently has a PE ratio of -11.70, a price-to-book (PB) ratio of 4.84, a price-to-sale (PS) ratio of 38.50, a price to cashflow ratio of 10.60, a PEG ratio of -, a ROA of -24.64%, a ROC of -31.02% and a ROE of -36.26%. The company’s profit margin is 8.38%, its EBITDA margin is -274.80%, and its revenue ttm is $98.18 Million , which makes it $0.72 revenue per share.

Of the last four earnings reports from Denali Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.83 for the next earnings report. Denali Therapeutics Inc.’s next earnings report date is 02nd Nov 2023.

The consensus rating of Wall Street analysts for Denali Therapeutics Inc. is Strong Buy (1.29), with a target price of $60.92, which is +193.59% compared to the current price. The earnings rating for Denali Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Denali Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Denali Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.59, ATR14 : 0.86, CCI20 : -156.99, Chaikin Money Flow : -0.23, MACD : -1.01, Money Flow Index : 28.08, ROC : -18.12, RSI : 23.42, STOCH (14,3) : 2.44, STOCH RSI : 0.00, UO : 26.67, Williams %R : -97.56), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Denali Therapeutics Inc. in the last 12-months were: Alexander O. Schuth (Option Excercise at a value of $136 200), Alexander O. Schuth (Sold 30 566 shares of value $856 489 ), Carole Ho (Sold 40 269 shares of value $1 115 668 ), Krognes Steve (Sold 6 466 shares of value $190 770 ), Marc Tessier-Lavigne (Sold 40 000 shares of value $1 215 063 ), Ryan J. Watts (Option Excercise at a value of $51 000), Ryan J. Watts (Sold 97 077 shares of value $2 759 474 ), SATO VICKI L (Sold 1 666 shares of value $49 709 ), Schuth Alexander (Sold 0 shares of value $-189 000 ), Schuth Alexander (Sold 51 191 shares of value $1 391 545 ), Steve E. Krognes (Sold 6 466 shares of value $190 770 ), Vicki L. Sato (Sold 3 332 shares of value $90 193 ), Watts Ryan (Sold 0 shares of value $-52 718 ), Watts Ryan (Sold 101 912 shares of value $2 874 860 )